A neonatal Fc receptor antagonist for the treatment of generalized myasthenia gravis:efgartigimod alfa
Efgartigimod alfa is a neonatal Fc receptor(FcRn)antagonist that significantly reduces serum IgG levels,in-cluding pathological acetylcholine receptor(AChR)antibodies,by binding to FcRn and inhibiting its interaction with IgG.On 30 June 2023,the National Medical Products Administration(NMPA)of China approved the marketing of efgartigimod alfa in-jection for the treatment of AChR antibody-positive adults with generalized myasthenia gravis(gMG).This article reviews its mechanism of action,pharmacokinetics,efficacy,and safety,aiming to provide a reference for its clinical application.
efgartigimod alfamyasthenia gravisneonatal Fc receptor
NETL
NSTL
万方数据
